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Abstract 6-Amino-2-thiouracil (1) was condensed with benzenesulfonyl chloride
and p-toluenesulfonyl chloride in presence of pyridine as an acid binder to give
sulfonamides 2a, b, which could be methylated in basic medium to give methyl-
mercapto derivatives 3a, b, which in turn reacted with bromine in glacial acetic acid
to yield 5-bromo derivatives 4a, b. On the other hand, compounds 2a, b were cy-
clocondensed with monochloroacetyl chloride, p-tolualdehyde in glacial acetic acid/
pyridine, and ethyl bromoacetate to give the corresponding thiazolopyrimidines 5a,
b, 6a, b, and 7a, b, respectively; also compounds 2a, b were hydrazinolyzed to
compounds 8a, b, which could be cyclized to triazolopyrimidines 9a, b in presence
of formic acid. They could also be condensed with p-anisaldehyde to give hydra-
zones 10a, b. In another pathway, compounds 2a, b were reacted with monochlo-
roacetic acid in basic medium to give acetic acid derivatives 11a, b. It can be
deduced from the preliminary screening results that the cell lines most sensitive to
the antiproliferative activity of tested compounds are human liver HEPG2 and colon
cancer HT-29. All selected compounds exhibited moderate to strong growth inhi-
bition activity against the HEPG2 cell line with 50 % inhibitory concentration
(IC50) ranging between 1 and 10 lg/ml. The most active compounds, which
revealed antiproliferative activity also against human colon HT-29 and breast MCF-
7 cell lines, were 3a, 3b, 4a, and 10a.
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Introduction
5-Fluorouracil (5-FU) is one of the oldest chemotherapy drugs [1] and has been in
use for decades. It is an active medicine against many cancers including colon,
rectal, pancreas, head, neck, and liver cancers [2]. It is also used topically as a cream
or solution to treat basal cell cancer of skin and actinic keratoses, thus becoming the
first prototype of pyrimidines in this field. Analogously, some 5-halogenated
thiouracils have been synthesized and screened for anticancer activity. It has been
reported that the tested compounds had comparable activity to that of uracils [3].
From 1957 to 2011, different research laboratories investigated the anticancer
activity of some 5- and 6-substituted 2-thiouracils and reported that the tested
compounds were found to inhibit DNA synthesis [4–11]. Based on these findings,
the present work aims to synthesize a new group of pyrimidine compounds
incorporated with different heterocycles to investigate whether the resulting
compounds have better biological activity as antiproliferative agents against cancer,
since all the selected pyrimidine derivatives were soluble in dimethyl sulfoxide
(DMSO) at sufficient concentrations to allow cell experiments. The in vitro
biological activity of these compounds was evaluated by their growth inhibitory
potency against different cancer cell lines. The cytotoxic potency of compounds 3a,
3b, 4a, 5b, 6a, 7b, 8a, 9b, 10a, and 11a was studied in comparison with the known
anticancer drugs 5-FU and cisplatin (CIS).
In continuation of our work on the synthesis of some 2-thiouracils [12], we report
here the synthesis of novel thiouracil derivatives based on the diverse medicinal
uses and biological activities of thiouracils as anticancer [12], antithyroid [13], and
anti-infective agents [13–15]. In this work we screened some of the prepared
compounds as anticancer agents in analogy to 5-FU, and we also develop a program
to incorporate the thiouracil nucleus into thiazole and triazole nuclei to compare
their activities with 5-FU as a reference standard, finally concluding that 5- and
6-substituted 2-thiouracils may have activity comparable to 5-FU.
Chemistry
All melting points are uncorrected and were determined in capillary tube on a
Boetius melting-point microscope. Infrared (IR) spectra (KBr, cm-1) were recorded
from KBr discs. 1H nuclear magnetic resonance (NMR) spectra were obtained on a
Joel EX 270-MHz spectrometer with tetramethylsilane (TMS) as internal standard.
Mass spectra were recorded on a SSQ 7000 mass spectrometer at 70 eV. All
reactions were followed and checked by thin-layer chromatography (TLC) using
chloroform/methanol (3:1), and spots were examined by ultraviolet (UV) lamp.
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6-Amino-2-thiouracil (1)




A mixture of 1 (1.42 g of 0.05 mol), benzenesulfonyl chloride (0.88 g of 0.05 mol)
or p-toluenesulfonyl chloride (0.95 g of 0.05 mol), and pyridine (0.4 ml) in
methanol (25 ml) was refluxed for 12 h, then cooled; the reaction mixture was
poured into ice/HCl, and the resulting solid formed was filtered off, washed with




An amount (0.05 mol) of 2a, b was dissolved in 25 ml 10 % alc. NaOH with
stirring, then methyl iodide (0.05 mol) was added with stirring for 4 h, then the





An amount (0.05 mol) of 3a, b was stirred with 0.05 mol bromine in 25 ml glacial
acetic acid for 24 h, then the produced solid was filtered off, washed several times




To an ice-cold solution of 2a, b (0.01 mol) in 40 ml dry DMF, triethylamine
(0.01 mol) and chloroacetyl chloride (0.01 mol) were added successively. The
reaction mixture was heated in a water bath at 70 C for 6 h, cooled, poured into
ice/cold water, and extracted with 3 9 30 ml methylene chloride; the organic layer
was dried on anhydrous sodium sulfate and filtered off, and the filtrate was
evaporated to dryness. The residue was washed with 10 % sodium carbonate
solution, and the undissolved solid was filtered off, and crystallized from DMF/
water.






A mixture of 2a, b (0.001 mol) and p-tolualdehyde (0.001 mol) in 30 ml glacial
acetic acid/acetic anhydride mixture was refluxed for 7 h, then cooled, and the




To an ice-cold solution of 2a, b (0.01 mol) in 40 ml dry DMF, triethylamine
(0.01 mol) and ethyl bromoacetate (0.01 mol) were added successively. The
reaction mixture was heated in a water bath at 70 C for 6 h, cooled, poured into
ice/cold water, and extracted with methylene chloride (3 9 30 ml); the organic
layer was dried on anhydrous sodium sulfate and filtered off, and the filtrate was
evaporated to dryness. The residue was washed with 10 % sodium carbonate
solution, and the undissolved solid was filtered off, and crystallized from DMF/
water.
2a
Yield 75 %, m.p. 274 C, Anal. Calcd. C10H9N3O3S2 (283.33): C, 42.34; H, 3.20;
N, 14.83. Found: C, 42.09; H, 3.45; N, 14.78; IR (KBr, cm-1): 3,300 (NH), 3,100
(CH aromatic), 1,668 (C=O of thiouracil), 1,140, 1,320 (SO2), 1,270 (C=S);
1H
NMR (DMSO-d6) 6.8 (1H, s, thiouracil), 7.1–7.4 (5H, m), 9.8, 10.2, 10.5 (3NH, s,
exchangeable with D2O); MS: m/z 283.3 (M
?, 27.1 %).
2b
Yield 57 %, m.p. 288 C, Anal. Calcd. C11H11N3O3S2 (297.36): C, 44.43; H, 3.73;
N, 14.13. Found: C, 44.72; H, 3.95; N, 14.06; IR (KBr, cm-1): 3,350 (NH), 3,100
(CH aromatic), 2,950 (CH, aliphatic), 1,676 (C=O of thiouracil), 1,143, 1,327 (SO2),
1,276 (C=S); 1H NMR (DMSO-d6) 2.5 (H3C-S), 6.7 (1H, s, thiouracil), 7.1–7.3 (4H,
dd), 9.6,10.410.7 (3NH, s, exchangeable with D2O); MS: m/z 297.4 (M
?, 39.3 %).
3a
Yield 63 %, m.p. 301 C, Anal. Calcd. C11H12N3O3S2 (297.36): C, 44.43; H, 3.73;
N, 14.13. Found: C, 44.09 H, 4.38; N, 13.99; IR (KBr, cm-1): 3,387 (NH), 2,978
(CH aliphatic), 3,167 (CH aromatic), 1,665 (C=O of thiouracil), 1,143, 1,325 (SO2),
1,274 (C=S); 1H NMR (DMSO-d6), 2.3 (H3C-S), 6.9 (1H, s, thiouracil), 7.1–7.3
(5H, m), 9.9, 10.5 (2NH, s, exchangeable with D2O); MS: m/z 297.4 (M
?, 15.8 %).
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3b
Yield 78 %, m.p. 361 C, Anal. Calcd. C12H14N3O3S2 (312.38): C, 46.13; H, 4.52;
N, 13.45, Found: C, 46.44; H, 4.66; N, 13.19; IR (KBr, cm-1): 3,348 (NH), 2,990
(CH aliphatic), 3,177 (CH aromatic), 1,685 (C=O of thiouracil), 1,148, 1,337 (SO2),
1,271 (C=S); 1H NMR (DMSO-d6), 2.3, 2.5 (2 H3C-S), 6.8 (1H, s, thiouracil),




Yield 80 %, m.p. 276 C, Anal. Calcd. C11H10N3O3S2 Br (376.27): C, 35.11; H,
2.68; N, 11.17. Found: C, 35.07 H, 2.57; N, 11.38; IR (KBr, cm-1): 3,355 (NH),
2,968 (CH aliphatic), 3,168 (CH aromatic), 1,678 (C=O of thiouracil), 1,139, 1,320
(SO2), 1,274 (C=S);
1H NMR (DMSO-d6), 2.4 (H3C-S), 7.1–7.3 (5H, m), 9.9, 10.4
(2NH, s, exchangeable with D2O); MS: m/z 376.3 (M
?, 18.1 %), 378.2 (M?2)?
(17.4 %).
4b
Yield 69 %, m.p. 298 C, Anal. Calcd. C12H12N3O3S2 Br (390.28): C, 36.92; H,
3.10; N, 10.77. Found: C, 37.01; H, 3.21; N, 10.82; IR (KBr, cm-1): 3,350 (NH),
2,968 (CH aliphatic), 3,139 (CH aromatic), 1,685 (C=O of thiouracil), 1,142, 1,328
(SO2);
1H NMR (DMSO-d6), 2.3, 2.4 (2 H3C-S), 7.2, 7.3 (4H, dd), 9.8, 10.2 (2NH,
s, exchangeable with D2O); MS: m/z 390.3 (M
?, 26.2 %), 392.7 (M?2)? (25.7 %).
5a
Yield 70 %, m.p. 253 C, Anal. Calcd. C12H9N3O4S2 (323.34): C, 44.57; H, 2.81;
N, 12.99. Found: C, 44.38; H, 2.97; N, 13.07; IR (KBr, cm-1): 3,300 (NH), 3,154
(CH aromatic), 1,668 (C=O of pyrimidine), 1,723 (C=O of thiazole), 1,140, 1,320
(SO2);
1H NMR (DMSO-d6), 2.2 (2H of thiazole) 6.8 (1H, s, pyrimidine), 7.1–7.4
(5H, m), 9.8 (1H, s, exchangeable with D2O); MS: m/z 323.3 (M
?, 16.1 %).
5b
Yield 68 %, m.p. 280 C, Anal. Calcd. C13H11N3O4S2 (337.38): C, 46.28; H, 3.29; N,
12.45. Found: C, 46.19; H, 3.40; N, 12.62; IR (KBr, cm-1): 3,320 (NH), 3,164 (CH
aromatic), 1,688 (C=O of pyrimidine), 1,721 (C=O of thiazole), 1,140, 1,320 (SO2);
1H NMR (DMSO-d6), 2.2 (2H of thiazole), 2.5 (3H, s), 6.8 (1H, s, pyrimidine), 7.1–7.3
(4H, dd), 9.7 (1H, s, exchangeable with D2O); MS: m/z 337.4 (M
?, 12.56 %).
6a
Yield 59 %, m.p. 308 C, Anal. Calcd. C20H15N3O4S2 (425.48): C, 56.45; H, 3.55;
N, 9.88. Found: C, 56.67; H, 3.47; N, 9.97; IR (KBr, cm-1): 3,354 (NH), 3,109 (CH
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aromatic), 1,680 (C=O of pyrimidine), 1,728 (C=O of thiazole), 1,140, 1,320 (SO2);
1H NMR (DMSO-d6), 2.1 (3H, s, CH3), 6.2 (1H, s, C=CH), 6.7 (1H, s, pyrimidine),




Yield 73 %, m.p. 319 C, Anal. Calcd. C21H17N3O4S2 (439.51): C, 57.34; H, 3.89;
N, 9.56. Found: C, 57.44; H, 3.87; N, 9.48; IR (KBr, cm-1): 3,377 (NH), 3,137 (CH
aromatic), 1,685 (C=O of pyrimidine), 1,730 (C=O of thiazole), 1,140, 1,320 (SO2);
1H NMR (DMSO-d6), 2.1, 2.2 (6H, s, 2 CH3), 6.2 (1H, s, C=CH), 6.9 (1H, s,
pyrimidine), 7.4–7.7 (8H, m), 9.4 (1H, s, exchangeable with D2O); MS: m/z 439.5
(M?, 48.09 %).
7a
Yield 77 %, m.p. 325 C, Anal. Calcd. C12H9N3O4S2 (323.34): C, 44.57; H, 2.81;
N, 12.99. Found: C, 44.56; H, 2.67; N, 13.20; IR (KBr, cm-1): 3,320 (NH), 3,174
(CH aromatic), 1,670 (C=O of pyrimidine), 1,727 (C=O of thiazole), 1,145, 1,323
(SO2);
1H NMR (DMSO-d6) 2.4 (2H of thiazole), 6.9 (1H, s, pyrimidine), 7.1–7.3
(5H, m), 9.8 (1H, s, exchangeable with D2O); MS: m/z (%) 323.3 (M)
? (10.76 %).
7b
Yield 65 %, m.p. 372 C, Anal. Calcd. C13H11N3O4S2 (337.38): C, 46.28; H, 3.29;
N, 12.45. Found: C, 46.37; H, 3.40; N, 12.58; IR (KBr, cm-1): 3,300 (NH), 3,157
(CH aromatic), 1,685 (C=O of pyrimidine), 1,722 (C=O of thiazole), 1,140, 1,320
(SO2);
1H NMR (DMSO-d6), 2.3 (2H of thiazole), 2.5 (3H, s, CH3), 6.8 (1H, s,
pyrimidine), 7.1–7.4 (4H, dd), 9.7 (1H, s, exchangeable with D2O); MS: m/z 337.4




A mixture of 2a, b (0.005 mol) and hydrazine hydrate 99 % (0.005 mol) in 30 ml
methanol was refluxed for 30 h, then cooled and poured into ice/water; the produced




A mixture of 8a, b (0.001 mol) and 30 ml formic acid was refluxed for 8 h, then
cooled and poured into ice/water; the precipitate was filtered off, dried, and
crystallized from methanol.






A mixture of 8a, b (0.001 mol) and p-anisaldehyde (0.001 mol) in 30 ml methanol
was refluxed for 8 h, then cooled, and the produced precipitate was filtered off,
dried, and crystallized from DMF/water.
[(4-{[Phenylsulfonyl]amino}-6-oxo-1,6-dihydropyrimidin-2-yl)sulfanyl]acetic
acid and [(4-{[(4-methylphenyl)sulfonyl]amino}-6-oxo-1,6-dihydropyrimidin-2-
yl)sulfanyl]acetic acid (11a, b)
To a solution of monochloroacetic acid (0.03 mol) and sodium hydroxide
(0.03 mol) in 5 ml water, a solution of 2a, b (0.03 mol) and sodium hydroxide
(0.03 mol) was added. The reaction mixture was stirred at ambient temperature for
3 h, then rendered acidic with hydrochloric acid (6 N). The separated solid was
filtered off, washed with water, dried, and crystallized from methanol.
8a
Yield 61 %, m.p. 277 C, Anal. Calcd. C10H11N5O3S (281.13): C, 42.72; H, 3.94;
N, 24.91. Found: C, 42.75 H, 3.70; N, 24.83; IR (KBr, cm-1): 3,301 (NH), 3,167
(CH aromatic), 1,665 (C=O of pyrimidine), 1,143, 1,325 (SO2);
1H NMR (DMSO-
d6), 3.1, 6.2, 6.8, 10.5 (NH2, 3NH, s, exchangeable with D2O), 6.9 (1H, s,







































Scheme 1 The structure of compounds: 3a,b–7a,b
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8b
Yield 70 %, m.p. 253 C, Anal. Calcd. C11H13N5O3S (295.32): C, 44.73; H, 4.44;
N, 23.72. Found: C, 44.58; H, 4.37; N, 23.86; IR (KBr, cm-1): 3,312 (NH), 3,176
(CH aromatic), 1,676 (C=O of pyrimidine), 1,143, 1,325 (SO2);
1H NMR (DMSO-
d6), 3.2, 6.4, 6.8, 10.3 (NH2, 3NH, s, exchangeable with D2O), 2.4 (3H, s, CH3), 6.7
(1H, s, pyrimidine), 7.1–7.4 (4H, dd); MS: m/z 295.3 (M?, 54.94 %).
9a
Yield 66 %, m.p. 267 C, Anal. Calcd. C11H9N5O3S (291.30): C, 45.35; H, 3.11; N,
24.05. Found: C, 45.07; H, 3.45; N, 23.97; IR (KBr, cm-1): 3,354 (NH), 2,978,
3,168 (CH aromatic), 1,675 (C=O of pyrimidine), 1,140, 1,327 (SO2);
1H NMR
(DMSO-d6), 6.9 (1H, s, thiouracil), 7.1 (1H, s, triazole), 7.2–7.4 (5H, m), 8.1, 9.5
(2NH, s, exchangeable D2O); MS: m/z 291.3 (M
?, 25.98 %).
9b
Yield 59 %, m.p. 295 C, Anal. Calcd. C12H11N5O3S (305.32): C, 47.19; H, 3.63;
N, 22.94. Found: C, 47.32; H, 3.57; N, 22.97; IR (KBr, cm-1): 3,300 (NH), 3,168
(CH aromatic), 1,679 (C=O of pyrimidine), 1,140, 1,327 (SO2);
1H NMR (DMSO-
d6), 2.5 (3H, s, CH3), 6.9 (1H, s, pyrimidine), 7.0 (1H, s, triazole), 7.1–7.3 (4H, dd),
8.2, 9.4 (2NH, s, exchangeable with D2O); MS: m/z 305.3 (M
?, 9.85 %).
10a
Yield 74 %, m.p. 321 C, Anal. Calcd. C18H17N5O4S (399.43): C, 54.12; H, 4.29;
N, 17.53. Found: C, 54.07; H, 4.35; N, 17.25; IR (KBr, cm-1): 3,391 (NH), 3,197
(CH aromatic), 1,675 (C=O of pyrimidine), 1,145, 1,328 (SO2);
1H NMR (DMSO-
d6), 4.1 (3H, s, OCH3), 6.1 (1H, s, CH=N–), 6.2, 6.8, 10.5 (3NH, s, exchangeable
with D2O), 6.9 (1H, s, pyrimidine), 7.1–7.4 (9H, m); MS: m/z 399.4 (M
?, 7.93 %).
10b
Yield 67 %, m.p. 347 C, Anal. Calcd. C19H19N5O4S (413.45): C, 55.19; H, 4.63;
N, 16.94. Found: C, 55.50; H, 4.57; N, 16.76; IR (KBr, cm-1): 3,388 (NH), 3,165
(CH aromatic), 1,687 (C=O of pyrimidine), 1,140, 1,326 (SO2);
1H NMR (DMSO-
d6), 2.5 (3H, s, CH3) 4.2 (3H, s, OCH3), 6.2 (1H, s, CH=N–), 6.1, 6.8, 10.4 (3NH, s,
exchangeable with D2O), 6.9 (1H, s, pyrimidine), 7.1–7.3 (8H, m); MS: m/z 413.5
(M?, 12.07 %).
11a
Yield 68 %, m.p. 335 C, Anal. Calcd. C12H11N3O5S2 (341.36): C, 42.22; H, 3.25;
N, 12.31. Found: C, 42.58; H, 2.98; N, 12.45; IR (KBr, cm-1): 3,405 (OH) very
broad due to hydrogen bonding, 3,300 (NH), 2,958 (CH– aliphatic), 3,167 (CH
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aromatic), 1,675 (C=O of thiouracil), 1,750 (CO of COOH), 1,143, 1,325 (SO2);
1H
NMR (DMSO-d6), 3.3 (2H, s, CH2), 6.9 (1H, s, pyrimidine), 7.1–7.4 (5H, m), 9.9,




Yield 60 %, m.p. 359 C, Anal. Calcd. C13H13N3O5S2 (355.39): C, 43.93; H, 3.69;
N, 11.82. Found: C, 43.69; H, 3.78; N, 11.78; IR (KBr, cm-1): 3,400 (OH) very
broad due to hydrogen bonding, 3,300 (NH), 2,960 (CH– aliphatic), 3,100 (CH
aromatic), 1,670 (C=O of thiouracil), 1,754 (C=O of COOH), 1,140, 1,322 (SO2);
1H NMR (DMSO-d6), 2.5 (3H, s, CH3), 3.4 (2H, s, CH2), 6.7 (1H, s, pyrimidine),
7.2–7.4 (4H, dd), 9.8, 10.3 (2NH, s, exchangeable with D2O), 11.8 (1H, s, COOH);
MS: m/z 355.4 (M?, 23.84 %) (Scheme 2).
Biological investigation
On the basis of monitoring the inhibition of the growth of human cancer cells, a
series of novel pyrimidine derivatives possessing a broader spectrum of antitumor
activity and fewer toxic side-effects than traditional anticancer drugs have been
studied.
Ten selected pyrimidine derivatives (3a, 3b, 4a, 5b, 6a, 7b, 8a, 9b, 10a, and 11a)
were subjected to screening for investigation of their antiproliferative potency
against human A549 (lung), MCF-7 (breast), HT-29 (colon), and HEPG2 (liver)
cancer cell lines.
The results indicate that the cell lines most sensitive to the antiproliferative
activity of tested compounds are human liver HEPG2 and colon HT-29. In the case

































Scheme 2 The structure of compounds: 8a,b–11a,b
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antiproliferative activity compared with other compounds. On the other hand, in the
case of colon cancer HT-29, only compound 4a showed moderate activity in
comparison with other compounds.
In this study, we have identified some pyrimidine derivatives as a novel class of
compounds with antiproliferative activity. The lead compounds were the most
potent in the biological assay employed (showing, e.g., improved growth inhibition
potential as compared with the reference anticancer drugs).
These experimental findings may provide support for use of these novel




Two groups of cell lines were used in this work: (1) The first group: A549 (human lung
cancer), MCF-7 (human breast cancer), and HT-29 (human colon cancer) are
maintained in the Institute of Immunology and Experimental Therapy, Wroclaw,
Poland. Cell lines A549 and HT-29 were cultured in medium Opti-MEM (Gibco,
Scotland, USA) and RPMI 1640 (IIET, Wroclaw, Poland) supplemented with 2 mM L-
glutamine, fetal bovine serum (5 %) (all from Sigma-Aldrich Chemie GmbH,
Steinheim, Germany), 100 U/ml penicillin and 100 lg/ml streptomycin (both from
Polfa Tarchomin S.A., Warsaw, Poland), and 1 mM sodium pyruvate (from Sigma-
Aldrich Chemie GmbH, Steinheim, Germany), only in case of HT-29 cell line. Cell line
MCF-7 was cultured in Eagle medium (IIET, Wroclaw, Poland) supplemented with
2 mM L-glutamine, 0.01 mg/ml insulin, 1 mM sodium pyruvate, fetal bovine serum
(10 %) (all from Sigma-Aldrich Chemie GmbH, Steinheim, Germany), and 100 U/ml
penicillin and 100 lg/ml streptomycin (both from Polfa Tarchomin S.A., Warsaw,
Poland). All lines were obtained from the American Type Culture Collection (Rockville,
MD, USA). Cells were cultured at 37 C in humid atmosphere saturated with 5 % CO2.
(2) The second group: HEPG2 (human liver cancer cell line), is maintained at the
National Institute of Cancer, Cairo University, Cairo, Egypt.
Compounds
Prior to usage, the newly synthesized compounds (3a, 3b, 4a, 5b, 6a, 7b, 8a, 9b,
10a, and 11a) were dissolved in DMSO and culture medium (1:9) to concentration
of 1 mg/ml and subsequently diluted in culture medium to reach the required
concentrations (ranging from 1 to 100 lg/ml).
Antiproliferative assay in vitro
At 24 h before addition of the tested compounds, the cells were placed in 96-well
plates (Sarstedt, Germany) at density of 1 9 104 cells per well. An assay was
1798 S. M. Awad et al.
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performed after 72 h of exposure to varying concentrations of the tested agents. The
in vitro cytotoxic effect of all agents was examined using the sulforhodamine B
(SRB) assay [18].
SRB cytotoxicity test
Cells were attached to the bottom of plastic wells by fixing them with cold 50 %
trichloroacetic acid (TCA; Sigma-Aldrich Chemie GmbH, Steinheim, Germany) on
the top of the culture medium in each well. The plates were incubated at 4 C for
1 h, then washed five times with tap water. The cellular material fixed with TCA
was stained with 0.04 % sulforhodamine B (SRB; Sigma-Aldrich Chemie GmbH,
Steinheim, Germany) dissolved in 1 % acetic acid (POCH, Gliwice, Poland) for
30 min. Unbound dye was removed by rinsing (49) in 1 % acetic acid. The protein-
bound dye was extracted with 10 mM unbuffered Tris base (POCH, Gliwice,
Poland) for determination of the optical density (k = 540 nm) in a computer-
interfaced, 96-well microtiter plate reader (Multiskan RC photometer; Labsystems,
Helsinki, Finland).
The results were calculated as an IC50 (50 % inhibitory concentration) value, i.e.,
the concentration of tested agent which inhibits proliferation of 50 % of the cancer
cell population. IC values were calculated for each experiment separately, and mean
values with standard deviation (SD) are presented in the table. Each compound at
each concentration was tested in triplicate in a single experiment, which was
repeated 3–7 times.
Results
Table 1 indicates the cytotoxic activity of the newly synthesized derivatives 3a, 3b,
4a, 5b, 6a, 7b, 8a, 9b, 10a, and 11a against various cancer cell lines. Their activity
was compared with the traditional anticancer drugs 5-FU and CIS. It can be deduced
from the preliminary screening results that the cell lines most sensitive to the
antiproliferative activity of tested compounds are human liver HEPG2 and colon
cancer HT-29. All selected compounds exhibited moderate to strong growth
inhibition activity against HEPG2 cell line with IC50 values ranging between 1 and
10 lg/ml. The most active compounds, which revealed antiproliferative activity
also against human colon HT-29 and breast MCF-7 cell lines, were 3a, 3b, 4a, and
10a.
Discussion
Cytotoxic drugs remain the mainstay of cancer chemotherapy, being administered in
novel therapeutic approaches such as signal inhibition. It is therefore important to
discover novel cytotoxic agents with spectra of activity and toxicity that differ from
currently used agents. It is well known that chemotherapy aims to destroy cancer
cells using various types of chemicals. The substances used are supposed to target
Synthesis and antiproliferative activity of new pyrimidine derivatives 1799
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mainly cancer cells, and doses are calculated to minimize collateral damage to
surrounding tissues, which nevertheless occurs. This type of treatment increases the
entropy of the organism, suppresses the immune system, and forms a toxic cell
environment which may destroy surrounding healthy cells. So, it is important to
minimize effective doses to the least amount, as well as to try to minimize the side-
effects of these drugs. Therefore, novel pyrimidine derivatives with a comparable
spectrum of antiproliferative activity to 5-FU, but potentially fewer side-effects,
were developed. The antiproliferative activities of such compounds were assessed
against the HEPG2 cancer cell line in comparison with the traditional anticancer
drugs 5-FU and CIS. In the antiproliferative activity study, some of the selected
compounds showed reasonable antiproliferative activity in comparison with 5-FU
and CIS. Moreover, study of the biochemical parameters induced in mice by the
tested compounds showed insignificant differences relative to the control group,
which indicates a moderate margin of safety for the selected compounds. Compared
with 5-FU and doxorubicin (DOX), dose augmentation of compounds 10a and 11a,
in a search for possibly higher potency, therefore seems realizable without
undesirable implications. Furthermore, the selected compounds have important
potential advantages over 5-FU and DOX because of their lower toxicity and their
ability to induce lower biochemical parameters. These results are in agreement with
the work of many authors who have reported novel derivatives of 5-FU with a
broader spectrum of antitumor activity and fewer toxic side-effects than 5-FU.
Table 1 Antiproliferative activity of some selected newly synthesized compounds against different
carcinoma cell lines
Compound IC50 (lg/ml)
A549 MCF-7 HT-29 HEPG2
3a na 51.69 ± 8.0 6.93 ± 1.65 4.1
3b 55.39 ± 6.53 40.51 ± 8.26 14.72 ± 3.56 3.92
4a na 67.86 ± 11.04 46.99 ± 9.21 4.31
5a na na na 9.38
6a na na na 6.59
7b na na na 6.53
8a na 54.41 ± 8.70 na 8.54
9b na na na 8.48
10a 41.77 ± 9.13 25.74 ± 4.47 14.35 ± 3.54 3.74
11a na na na 7.43
Cisplatin 4.08 ± 0.43 3.34 ± 0.52 4.30 ± 3.67 3.58
5-Fluorouracil 7.22 ± 0.44 3.65 ± 0.93 0.37 ± 0.28 5
DMSO na* na* na* na*
na not active at tested concentration (from 100 to 0.1 lg/ml), na* not active at the highest concentration
of DMSO (1 % solution)
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Conclusions
Various compounds were selected for further structural modification in an effort to
increase their potency. The goal of the present work is to explore the significance of
the spacer for the respective biological anticancer activity. The anticancer activity
data indicate that the cell lines most sensitive to the activity of tested compounds are
human liver HEPG2 and colon cancer HT-29. In the case of human liver HEPG2,
compounds 3a, 3b, 4a, and 10a showed the highest antiproliferative activity
compared with other compounds. On the other hand, in the case of colon cancer HT-
29, only compound 3a showed moderate activity in comparison with other
compounds.
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